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Abstract 
Background: Adjunctive systemic antibiotic therapy for treatment of bacterial endophthalmitis 
is controversial but common practice due to the severity of the disease. In absence of guidance 
documents, several antibiotic regimens are being used without applying evidence-based 
prescribing, thus leading to inappropriate treatment of this serious eye condition.  
Objectives: To summarize available data on intravitreal penetration of systemically 
administered antibiotics and to discuss their usefulness from a microbiological and 
pharmacological point of view. 
Sources: We performed a systematic PubMed search of studies investigating antibiotic 
concentrations in the vitreous after systemic administration in humans, and selected animal 
models. 
Content: The best-documented agents achieving therapeutic levels in the vitreous are 
meropenem, linezolid and moxifloxacin. Vancomycin, cefazoline, ceftriaxone, ceftazidime, 
imipenem and trimethoprim-sulfamethoxazole reach levels justifying their use in specific 
situations. Available data do not support the use of ciprofloxacin, levofloxacin, 
aminoglycosides, aminopenicillins, piperacillin, cefepime, and clarithromycin. With very 
limited but available promising data, the use of daptomycin and rifampicin deserves further 
investigation. 
Implications: The choice of the adjunctive systemic antibiotic agent – in situations where 
considered relevant for treatment - must to date be made on an individual base, considering 
microbiological aspects as well as operative status and inflammation of the eye. This review 
gives a systematic overview of antibiotic options and provides guidance to the clinician striving 
for optimal systemic antibiotic treatment of bacterial endophthalmitis. 
  
Introduction 
Vitrectomy and intravitreal antibiotics are nowadays considered as the gold standard treatment 
of bacterial endophthalmitis [1]. Adjunctive use of systemic antibiotics is controversial but 
common practice justified by the severity of the disease. Data on intravitreal antibiotic levels 
reached by systemic administration are sparse and comprehensive recommendations for 
systemic use have not been established [1–3]. The availability of new antibiotic agents, 
changing resistance patterns, and new surgical techniques using implants such as 
keratoprosthesis justify revisiting their systemic use for endophthalmitis. 
This review summarizes available data on intravitreal penetration of systemically administered 
antibiotics and discusses preferred regimens for the treatment of bacterial endophthalmitis from 
a microbiological and pharmacological perspective. 
Definition and commonly isolated microorganisms 
Endophthalmitis refers to the inflammation of the internal eye affecting the vitreous cavity and 
the anterior chamber, resulting from exogenous (mostly surgery related) or, more rarely (5-
10%) hematogenous insertion of microorganisms [4]. 
The most commonly isolated microorganisms are coagulase-negative staphylococci (40-70%), 
Staphylococcus aureus (10-17%), streptococci (5-15%), other Gram-positive cocci including 
enterococci (5%), as well as Gram-negative bacilli (5-10%) including Haemophilus influenzae 
and Pseudomonas aeruginosa [5–8]. The microbiologic spectrum of less common forms like 
post-traumatic or endogenous endophthalmitis is more varied. For instance, bacillus sp. is 
regularly found after open-globe injuries [9]. The bacterial spectrum encountered may further 
vary according to local epidemiology and peri-operative prophylactic regimens [10].  
Current treatment recommendations 
The current mainstays of bacterial endophthalmitis treatment are vitrectomy and intravitreal 
antibiotics [1]. Vitrectomy aims to reduce the bacterial load with the intention of a local “source 
control”. Although complete vitrectomy would ensure maximal eradication of the infected 
tissue, partial vitrectomy is often preferred in clinical practice, because of the lower associated 
risk of iatrogenic retinal detachment.  
Intravitreal antibiotics are injected immediately after vitrectomy and their administration is 
usually repeated after 48 hours if the clinical course is not favourable. The most commonly 
used regimens are vancomycin combined with ceftazidime or amikacin. The downside of 
repeated injections is an increased risk of retinal toxicity. 
Intravitreal dexamethasone is often added to reduce intraocular inflammation despite 
conflicting evidence [1]. Corticosteroids accelerate blood-retinal barrier restitution and thus 
influence antibiotic penetration.  
The role of systemic antibiotics 
The single large clinical trial evaluating the role of systemic antibiotics for the treatment of 
endophthalmitis is the Endophthalmitis-Vitrectomy-Study conducted in the 1990s [11]. In this 
randomized study, no significant difference in visual acuity was found in patients receiving 
intravitreal antibiotics followed by intravenous antibiotic therapy compared to patients 
receiving only intravitreal treatment. However, this finding has been questioned because of the 
exclusion of patients with severe endophthalmitis and the choice of adjunctive antibiotics: 
ceftazidime has poor activity against the dominant Gram-positive organisms and amikacin has 
very limited intraocular penetration. Since then, only small studies have evaluated the efficacy 
of systemic antibiotic therapy in endophthalmitis with varying methodologies and results [12-
13]. 
Some recommendations advocate the adjunctive use of systemic antibiotics in severe acute 
purulent postoperative endophthalmitis [1]. Recommended regimens include vancomycin 
combined with ceftazidime [14] or imipenem with ciprofloxacin [15]. For the treatment of 
endogenous endophthalmitis the use of systemic antibiotics is undisputed [2, 4] . 
The pharmacokinetic rationale for adjunctive systemic antibiotics is the rapid elimination of 
intravitreally applied antibiotics, with almost complete removal after 24h [16], whereas 
systemic administration favors intraocular antibiotic accumulation over time.  
Discussing the controversial benefit of adjunctive systemic antibiotics in terms of visual 
outcome is beyond the scope of this review. The imminent poor outcome constitutes a strong 
argument for clinicians to use systemic therapy. We strongly believe that adjunctive systemic 
therapy should not be denied on an individual base, provided that all efforts are made to isolate 
the causative pathogen and to apply evidence-based prescribing of antibiotic agents. 
Intravitreal penetration of systemic antibiotics 
Factors determining the penetration of antibiotics into the eye 
The penetration of antibiotics into the posterior segment of the eye after systemic 
administration is limited by two blood-retinal barrier mechanisms (BRB): The retinal pigment 
endothelial cells located within the retinal cell layers (outer BRB) and the retinal capillary 
endothelial cells (inner BRB) [17]. Of note, entry into the anterior segment of the eye is limited 
by the blood-aqueous-barrier characterized by less restrictive properties, thereby resulting in 
different aqueous and vitreous drug concentrations. 
Drug permeability across the blood-retinal barriers depends on drug characteristics such as the 
molecular size, lipophilicity, ionization and protein binding. Of interest, BRB was shown to be 
more permeable than the blood-brain-barrier (BBB) owing to morphological differences [17]. 
As in the BBB, ocular inflammation increases drug permeability across the BRB. 
Elimination of antibiotics from the vitreous occurs via two routes: passive diffusion to the 
anterior chamber and through the Schlemm’s channel (anterior route), and retrograde transport 
through the blood-retinal barrier (posterior route). Clearance pathways from the vitreous 
depends not only on physico-chemical drug properties and ocular inflammation, but also on 
the surgical status [18]. Post-operative aphakia – after removal of an artificial intra-ocular lens 
– as well as vitrectomy influence elimination of antibiotics [19]. 
Pharmacokinetic studies 
1) The knowledge of antibiotics pharmacokinetics in the eye is derived from two types of 
studies: single concentration measurements in human eyes performed at the time of 
surgery, and rabbit models allowing for repetitive drug measurements. Several 
limitations should be considered: although single drug measurements are of high value 
for antibiotics characterized by a concentration-dependent killing effect 
(aminoglycosides, daptomycin), this approach is less informative for antibiotics with a 
killing profile that depends on time-above-MIC (beta-lactams) or AUC/MIC 
(fluoroquinolones, vancomycin, linezolid). 
2) Common pharmacodynamic index values (such as Cmax/MIC used in most of the 
assessed studies) do not necessarily reflect efficacy in the complex microenvironment 
of the eye.  
3) Comprehensive MIC-studies of endophthalmitis isolates are missing. In this review we 
use EUCAST breakpoints and wild-type distributions (ECOFF) [20] (table 2) as a 
reference to estimate potential efficacies of antibiotics.  
4) Animal studies must be interpreted with caution, as they do not fully reflect the 
pharmacokinetics in humans.  
Suitable publications were identified by a PubMed search using the terms [antibiotic name] 
and [vitreous] and [systemic/oral/intravenous]. If no publications were found, the search was 
complemented by the terms [eye] and [penetration]. Rabbit model studies were included for 
antibiotics with limited human data or if they provided additional relevant information. Studies 
are summarized in table 1.  
Review of available literature 
Vancomycin 
Vancomycin did not show any accumulation in phakic (including inflamed) eyes in a rabbit 
study [21]. Aphakic-vitrectomized eyes showed vitreous levels just above breakpoints of 
commonly involved Gram-positive organisms after one dose. In aphakic eyes, comparable 
levels were only reached after prolonged therapy. The poor intravitreal penetration of 
vancomycin is consistent with the limited CSF penetration [22] and explained by its high 
molecular weight and hydrophilicity. 
The rationale for its continued empiric use [14] despite limited data, is its microbiological 
spectrum covering almost 100% of Gram-positive organisms causing endophthalmitis [7]. 
Available data nevertheless suggest that systemic administration should only be considered in 
aphakic eyes. Given the delay in achieving sufficient concentrations, systemic administration 
should follow immediately intravitreal injection of the same agent.  
Penicillins 
Poor vitreal penetration of ampicillin and amoxicillin were demonstrated in rabbit models [23-
24]. Similarly, insufficient vitreous concentrations of piperacillin were demonstrated in human 
eyes with diverse operative status [25]. The vitreal penetration of penicillin G has not been 
studied but based on CSF penetration data [22] and drug properties, penetration into the 
vitreous is anticipated to be minimal. Nevertheless, in analogy to CSF infections, high systemic 
doses might provide effective vitreous levels for streptococcal endophthalmitis. 
Available data suggest that systemic administration of most penicillins is not appropriate to 
treat endophthalmitis. Penicillin G vitreous levels remain to be investigated.  
Cephalosporins 
Cefazoline vitreous concentrations are issued from a large rabbit study [26] showing levels 
well above streptococcal breakpoints in aphakic-vitrectomized inflamed eyes but undetectable 
levels in phakic non-inflamed eyes. 
Ceftriaxone was detectable in human phakic non-inflamed eyes after multiple dosing [27] at 
levels well above streptococci and enterobacteriaceae breakpoints, but below the ECOFF of 
S.aureus. Whether the observed levels result from accumulation after repetitive dosing, or rapid 
penetration as previously shown in CSF studies [28], is not known. 
Vitreous levels of ceftazidime are based on two rabbit studies [29-30]. Levels were above 
enterobacteriaceae breakpoints in aphakic-vitrectomized inflamed eyes. Only delayed 
penetration was observed in non-vitrectomized inflamed eyes and undetectable levels were 
found in phakic non-inflamed eyes [29]. 
Cefepime showed low vitreous levels in human phakic non-inflamed eyes [31], nonetheless 
penetration in inflamed eyes have not been studied. 
In summary, cefazoline, ceftriaxone and ceftazidime can be considered as targeted therapy 
when the pathogen is identified and the MIC of the isolate has been determined, yet on a thin 
evidence base. Ceftazidime is likely to be effective against most enterobacteriaceae in aphakic-
vitrectomized eyes. Since it exhibits very limited anti-streptococcal and no anti-staphylococcal 
activity, it should not be used to cover Gram-positive organisms. Cefepime cannot be 
recommended as observed levels are clearly below those of other cephalosporins, yet 
investigation in inflamed eyes is warranted. Neither ceftazidime nor cefepime can be 
recommended to treat pseudomonas endophthalmitis based on available data. 
Carbapenems 
Two studies in human phakic non-inflamed eyes showed imipenem vitreous concentrations 
around 2.0 ug/ml [32-33]. Meropenem was shown to rapidly achieve four-fold higher vitreous 
concentrations in a comparable study [34]. This finding is consistent with observed high 
meropenem levels in CSF [22] and explained by favorable physicochemical properties. Unlike 
imipenem, the observed levels of meropenem clearly exceed breakpoints for relevant Gram-
positive and Gram-negative organisms.  
The potential value of carbapenems in empirical treatment – as single agents - is limited by the 
high prevalence of oxacillin-resistent coagulase negative staphylococci also in ophthalmic 
isolates [8]. For empiric combination therapy, we would advocate the use of meropenem rather 
than imipenem based on the above-discussed data. Furthermore, meropenem appears to be the 
preferred option for targeted Pseudomonas treatment, particularly when considering the 
insufficient concentrations of ciprofloxacin, piperacillin, ceftazidime and cefepime as 
discussed above.  
Rifampicin 
High rifampicin vitreous levels were observed in phakic non-inflamed rabbit eyes [35], 
however with doses that, corrected for weight, would largely exceed tolerated doses in humans.  
Human studies are limited to aqueous levels, observed to be 0.2-1.3 ug/ml [36]. As rifampicin 
vitreous levels were consistently shown to be half of aqueous levels [31], human vitreous levels 
could be expected to exceed 0.1 ug/ml, which is well above breakpoints for staphylococci. 
A role of rifampicin in endophthalmitis after foreign-body implantation, incomplete 
vitrectomy, and aggressive S.aureus-infection deserves further consideration due to its 
bactericidal and biofilm-active-properties. Importantly, rifampicin has to be combined with an 
effective second anti-staphylococcal agent to prevent resistance. 
Linezolid 
Mean vitreous levels of linezolid in phakic non-inflamed human eyes range from 1.2 to 3.7 
ug/ml after one dose [37–40], with two studies showing further accumulation after two doses 
(4.5 and 5.7 ug/ml) [37, 39]. The good penetration into the vitreous is consistent with CSF 
penetration [22].  
Considering breakpoints of Gram-positive organisms, sufficient vitreous levels are likely to be 
attained after two doses. The drug, however, is bacteriostatic.  
The well documented ocular penetration and comprehensive coverage of Gram-positive germs 
make of linezolid a potential alternative to vancomycin. Caution is needed due to its toxicity 
(myelosuppression, peripheral neuropathy, optic neuropathy), although relatively infrequent in 
short-term administration [41].  
Daptomycin 
Knowledge of daptomycin penetration is limited to one case report of a patient treated for 
MRSA-endophthalmitis in a strongly inflamed, phakic, non-vitrectomized eye [42]. Single 
dose administration (10 mg/kg) resulted in a vitreous concentration of 12.4 ug/ml 42h post 
administration (patient had renal insufficiency). This finding appears promising considering 
low staphylococcal breakpoints and the drug’s bactericidal properties, but its use remains 
experimental to date. 
Aminoglycosides 
Vitreous concentrations far below breakpoints of relevant pathogens were shown after 
intravenous administration of amikacin and gentamycin in a rabbit study [43], despite study 
conditions expected to enhance vitreous levels (inflammation, aphakia and vitrectomy).  
Given the availability of better alternatives, there is no role for systemic administration of 
aminoglycosides in endophthalmitis. 
Fluoroquinolones 
Despite relatively good vitreous/serum (V/S) ratios owing to favourable physicochemical 
properties, observed concentrations in vitreous proved insufficient for ciprofloxacin [44–50] 
and levofloxacin [38, 51-52]. 
Moxifloxacin demonstrated concentrations well above breakpoints of relevant organisms after 
two doses [53-54], whereas concentrations were significantly lower after a single dose [55-56]. 
The low concentrations of the Vedantham study can be explained by an inadequate short 
sampling time of 90 minutes after oral administration [56] . Moxifloxacin maximal CSF levels 
were shown to occur 2-3 hours after maximal systemic levels [57].  
In summary, there are sufficient data to oppose the use of ciprofloxacin and levofloxacin for 
the treatment of endophthalmitis. Conversely, several studies consistently demonstrating 
satisfactory moxifloxacin levels are available. Given the observed higher levels with 
moxifloxacin 800mg, this increased dosage can be considered with a careful monitoring for 
side effects. Safety data on this dosage are not comprehensive to date [58].  
Moxifloxacin lacks activity against most oxacillin-resistant coagulase-negative staphylococci 
[8]), and streptococci rapidly develop resistance particularly when drug concentrations are low. 
Therefore, the use of moxifloxacin for empirical treatment of endophthalmitis is limited. 
Trimethoprim-Sulfamethoxazole 
Sulfonamides and trimethoprim have demonstrated a moderate penetration in the vitreous in 
one human study [59]. The  doses used, however, were below those for the treatment of 
meningitis [60]. The observed concentrations are not exceeding breakpoints of all relevant 
organisms although higher concentrations might be reached with increased doses. 
Concentrations are far below the breakpoint of Stenotrophomonas maltophilia (4 ug/ml) 
suggesting difficulty in treating this pathogen.  
Due to limited data and better alternatives for Gram-positive organisms, there is no current role 
for TMP/SMX in systemic endophthalmitis treatment. 
Clarithromycin 
Based on one human study of phakic non-inflamed eyes showing insufficient vitreous levels 
[61], there is no argument to recommend clarithromycin for endophthalmitis treatment. 
Similarly insufficient levels have been reported in CSF, where the use of clarithromycin is 
limited to case reports of successful treatment of atypic organisms [22]. 
Conclusion 
Data on the intravitreal concentrations of systemic antibiotics are generally scarce and are 
based on a single study for many agents. Relatively good evidence exists for therapeutic 
vitreous levels of meropenem, linezolid and high-dose moxifloxacin. None covers the required 
bacterial spectrum when used empirically as single agents, but the combination of linezolid 
with meropenem in empirical treatment of endophthalmitis may offer broad activity against the 
majority of pathogens. Vancomycin, cefazoline, ceftriaxone, ceftazidime, imipenem, 
daptomycin and TMP-SMX exhibit levels supporting their use in specific situations for 
targeted therapy. The operative status of the infected eye needs also to be considered. Available 
data do not support the use of ciprofloxacin, levofloxacin, aminoglycosides, aminopenicillins, 
piperacillin, cefepime or clarithromycin. Rifampicin may be considered for combination 
therapy in complicated staphylococcal infections. Further data on daptomycin vitreous 
penetration would be valuable. 
The choice of the adjunctive systemic antibiotic agent – in situations where considered relevant 
for treatment - must to date be made on an individual base, taking into account suspected or 
detected organisms, operative status, intraocular inflammatory activity and drug side effect 
profiles. Future research should assess the clinical outcome after use of systemic antibiotics 
with documented good intraocular penetration (e.g. meropenem, linezolid and moxifloxacin), 
and assess the role of rifampicin for staphylococcal infections. 
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